Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06135376

E-PAUse: Encouraging Proper Antibiotic Use in Outpatient Setting

Specific Aim 1: To determine the knowledge, attitude, and practice (KAP) of PHCC physicians regarding appropriate prescription of antibiotics in the outpatient setting.

Hypothesis 1a: PHCC physicians will have adequate theoretical knowledge regarding use of antibiotics for upper respiratory tract infections.

Hypothesis 1b: Despite adequate theoretical knowledge, fear of complications of untreated infection and patient demand and expectations will drive inappropriate antibiotic prescription for upper respiratory tract infections

Specific Aim 2: To test the effectiveness of a comprehensive multi-component intervention in a cluster randomized trial upon rate of antibiotics prescription for upper respiratory tract infections in individuals aged > 2 years presenting to primary care by PHCC physicians Hypothesis 2: Compared with a single intervention, a comprehensive multi-component intervention package will be associated with a significant reduction in inappropriate antibiotic prescription.

Investigators will conduct this study in the Primary Healthcare Center (PHCC) setting in Qatar. Investigators will identify four large PHCCs from the existing active centers. The study has 2 parts. Part 1 corresponds to specific aim 1 and comprises of a KAP survey which will be carried out in all four PHCCs and will include all physicians. Part 2 corresponds to specific aim 2 and is a cluster randomized clinical trial in which Investigators will randomize the four PHCCs into two groups.

First group (2 PHCCs) will receive training in appropriate documentation of infections and antibiotics prescription and will continue to provide usual care. Second group (2 PHCCs) will receive the comprehensive multi-component intervention, which consists of four elements:

1. Option for deferred prescription fulfilment; 2. Education of staff regarding appropriate uses of antibiotics, 3. algorithm-driven decision support tool, 4. Feedback on individual and group performance.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Drug Use

Age range

2 year–120 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PHCC

Doha, Qatar

About this study

As above.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >2 years old presenting to any of the selected PHCCs (rationale: signs and symptoms of bacterial infection in very young children are more non-specific and empiric antibiotics are often indicated due to serious consequences of unrecognized and untreated bacterial infections)
  • Presenting with acute (<1 week of symptoms) upper respiratory tract infection (URTI) like illness including
  • common cold/acute rhinitis/nasopharyngitis
  • laryngitis/laryngotracheitis
  • Acute bronchitis
  • acute otitis media
  • influenza (confirmed or influenza-like illness)
  • pharyngitis/tonsillitis
  • acute sinusitis

Exclusion criteria

  • Known immune compromised status, e.g., cystic fibrosis, cancer, organ transplant recipient.
  • On immune suppressive therapy for any duration (e.g., steroids, disease modifying antirheumatic agents; cancer chemotherapy, anti-rejection drugs, etc.) in one year prior to presentation
  • Known or diagnosed bacterial cause of infection.
  • Severe systemic illness requiring referral to the emergency department or hospitalization within 24 hours of presentation
  • Known or suspected chronic obstructive pulmonary disease. Asplenic patients (anatomic or functional)

Treatment and study plan

comprehensive multi-component interventions

Behavioral

It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.

Primary outcomes

  1. Total number of antibiotics courses prescribed for URTIs

    Time frame: Primary Analysis 11 months; Final analysis 24 months

    For each recorded diagnosis of URTI, investigators will count the number of persons who received an antibiotic prescription. All prescriptions regardless of drug, dose, route of administration and duration will be counted. Only one prescription per 30-day period will be counted to exclude those with ongoing, evolving, or unresolved infection.

  2. Proportion of antibiotics prescription dispensed for an inappropriate use

    Time frame: Total 11 months for primary analysis; Follow-up up to 36 months

    For each antibiotic prescription written for a URTI diagnosis, investigators will determine the appropriateness of antibiotics based on our previously published criteria.

Secondary outcomes

  1. Rates of hospitalization in 28 days after the PHCC visit

    Time frame: Total 11 months for primary analysis; Follow-up up to 36 months

    Number of hospitalizations within 28 days of the index visit

  2. Rates of ED visits in 28 days after the PHCC visit

    Time frame: Total 11 months for primary analysis;

    Number of ED visits within 28 days of the index visit

Sponsors and collaborators

Lead sponsor

Hamad Medical Corporation

Industry

Collaborators

  • Primary Health Care Corporation, Qatar

Registry information

Acronym: E-PAUse

Important dates

Study start
2023
Primary completion
2024
Study completion
2026
First posted
Nov 18, 2023
Registry last updated
Apr 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.